Kinetic mechanism of protein arginine methyltransferase 1.

Protein arginine methyltransferases (PRMTs) are SAM-dependent enzymes that catalyze the mono- and dimethylation of peptidyl arginine residues. Although all PRMTs produce monomethyl arginine (MMA), type 1 PRMTs go on to form asymmetrically dimethylated arginine (ADMA), while type 2 enzymes form symmetrically dimethylated arginine (SDMA). PRMT1 is the major type 1 PRMT in vivo, thus it is the primary producer of the competitive NOS inhibitor, ADMA. Hence, potent inhibitors, which are highly selective for this particular isozyme, could serve as excellent therapeutics for heart disease. However, the design of such inhibitors is impeded by a lack of information regarding this enzyme's kinetic and catalytic mechanisms. Herein we report an analysis of the kinetic mechanism of human PRMT1 using both an unmethylated and a monomethylated substrate peptide based on the N-terminus of histone H4. The results of initial velocity and product and dead-end inhibition experiments indicate that PRMT1 utilizes a rapid equilibrium random mechanism with the formation of dead-end EAP and EBQ complexes. This mechanism is gratifyingly consistent with previous results demonstrating that PRMT1 catalyzes substrate dimethylation in a partially processive manner.

[1]  P. Vallance,et al.  Disruption of methylarginine metabolism impairs vascular homeostasis , 2007, Nature Medicine.

[2]  Christopher K. Glass,et al.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.

[3]  P. Vallance,et al.  The DDAH/ADMA/NOS pathway. , 2003, Atherosclerosis. Supplements.

[4]  Xing Zhang,et al.  Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. , 2003, Structure.

[5]  S. Clarke,et al.  The Mammalian Immediate-early TIS21 Protein and the Leukemia-associated BTG1 Protein Interact with a Protein-arginine N-Methyltransferase* , 1996, The Journal of Biological Chemistry.

[6]  C. Allis,et al.  Methylation of Histone H4 at Arginine 3 Facilitating Transcriptional Activation by Nuclear Hormone Receptor , 2001, Science.

[7]  P. Vallance,et al.  Cardiovascular Biology of the Asymmetric Dimethylarginine:Dimethylarginine Dimethylaminohydrolase Pathway , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[8]  C. D. Krause,et al.  FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues. , 2006, Biochemical and biophysical research communications.

[9]  P. Vallance,et al.  S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Lang Li,et al.  Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen‐independent status , 2004, Cancer.

[11]  R. Trievel,et al.  Kinetic manifestation of processivity during multiple methylations catalyzed by SET domain protein methyltransferases. , 2007, Biochemistry.

[12]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[13]  P. Thompson,et al.  In situ generation of a bisubstrate analogue for protein arginine methyltransferase 1. , 2008, Journal of the American Chemical Society.

[14]  Ted M. Lakowski,et al.  A Kinetic Study of Human Protein Arginine N-Methyltransferase 6 Reveals a Distributive Mechanism* , 2008, Journal of Biological Chemistry.

[15]  F. Bachand,et al.  Protein Arginine Methyltransferases : from Unicellular Eukaryotes to Humans , 2007 .

[16]  H. Katus,et al.  Expression of nitric oxide related enzymes in coronary heart disease , 2006, Basic Research in Cardiology.

[17]  W. Cleland,et al.  Inhibition of creatine kinase by chromium nucleotides. , 1973, The Journal of biological chemistry.

[18]  Xing Zhang,et al.  Protein arginine methyltransferase 1: positively charged residues in substrate peptides distal to the site of methylation are important for substrate binding and catalysis. , 2007, Biochemistry.

[19]  Ya-Li Yao,et al.  Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. , 2003, Genes & development.

[20]  R. Roeder,et al.  Ordered Cooperative Functions of PRMT1, p300, and CARM1 in Transcriptional Activation by p53 , 2004, Cell.

[21]  D. Tsikas,et al.  LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. , 2000, Circulation research.

[22]  Brian D. Strahl,et al.  Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1 , 2001, Current Biology.

[23]  M. Bedford,et al.  Arginine methylation at a glance , 2007, Journal of Cell Science.

[24]  C. D. Krause,et al.  Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. , 2007, Pharmacology & therapeutics.

[25]  I. H. Segel.  Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .

[26]  G. L. Kenyon,et al.  Use of pH studies to elucidate the catalytic mechanism of rabbit muscle creatine kinase. , 1981, Biochemistry.

[27]  Xiaodong Cheng,et al.  Crystal structure of the conserved core of protein arginine methyltransferase PRMT3 , 2000, The EMBO journal.

[28]  Mark T Bedford,et al.  Arginine methylation an emerging regulator of protein function. , 2005, Molecular cell.

[29]  M. Stallcup,et al.  Synergistic Enhancement of Nuclear Receptor Function by p160 Coactivators and Two Coactivators with Protein Methyltransferase Activities* , 2001, The Journal of Biological Chemistry.

[30]  P. Meltzer,et al.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. , 1997, Science.

[31]  Kerstin Neubert,et al.  DRE-1: an evolutionarily conserved F box protein that regulates C. elegans developmental age. , 2007, Developmental cell.

[32]  M. Covic,et al.  Protein arginine methyltransferase 1 coactivates NF-kappaB-dependent gene expression synergistically with CARM1 and PARP1. , 2008, Journal of molecular biology.

[33]  L. Pearl,et al.  Insights into histone code syntax from structural and biochemical studies of CARM1 methyltransferase , 2007, The EMBO journal.

[34]  C. Abramovich,et al.  A protein‐arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor , 1997, The EMBO journal.

[35]  R. Espinosa,et al.  Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Pamela A. Silver,et al.  The structure and oligomerization of the yeast arginine methyltransferase, Hmt1 , 2000, Nature Structural Biology.

[37]  P. Meltzer,et al.  A Nuclear Factor, ASC-2, as a Cancer-amplified Transcriptional Coactivator Essential for Ligand-dependent Transactivation by Nuclear Receptors in Vivo * , 1999, The Journal of Biological Chemistry.

[38]  J. Mohler,et al.  Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability , 2006, The Prostate.